Physician profile
Catherine E Lindsay
NPI 1639369598
$14,000.36
in general payments reported to CMS, 2019-2025
55 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $2,207 · 2021: $2,542 · 2022: $1,471 · 2023: $2,063 · 2024: $1,978 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,762 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,762.45 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,394.71 | 2019-2025 | |
| Novo Nordisk INC | $1,442.37 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $972.69 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $936.77 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Optinose US, INC. | $930.09 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $824.44 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $652.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $633.48 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $393.66 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $350.24 | 2020-2021 | |
| Daiichi Sankyo INC. | $321.74 | 2019-2025 | Injectafer |
| Avanir Pharmaceuticals, INC. | $304.15 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.26 | 2023-2025 | |
| Corcept Therapeutics | $285.06 | 2020-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $255.23 | 2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.